Dettagli per singolo studio

DEC-NET Serial number GB284

Published online	09/07/2004 16.00.00
Last updated	02/08/2005 14.23.18

Other protocol ID number	N0016131957
This trial has been approved by an ethics committee
Current trial status	Closed to recruitment of participants: follow-up continuing
First subject enrolment Target N. of subjects	11/2001 15
Major Disease (ICD9 class)	CONGENITAL HEREDITARY MUSCULAR DYSTROPHY
Experimental drug
SALBUTAMOL Treatment regimen (dosage and duration) N/A
Gender	Both
Age (range)	5-20 years
Eligibility criteria
Inclusion criteria
7 male, 8 female, ages 5-20. Diagnosis of minicore
Exclusion criteria
Patients receiving salbutamol for other reasons informed consent not received
Trial design/methodology
Phase	4
Kind of study	Efficacy
Design	Pilot trial
Purpose of study
To determine if treatment with salbutamol, which has already been successfully used in other neuromuscular diseases, might be beneficial to patients with minicore myopathy.
Primary outcomes
To evaluate the role of this compound in Minicore disease.


Summary of study design, objectives, and ongoing research findings
Pilot trial to determine if treatment with salbutamol, which has already been successfully used in other neuromuscular diseases, might be beneficial to patients with minicore myopathy.